

広島大学学術情報リポジトリ

Hiroshima University Institutional Repository

Title	The EP4-ERK-dependent pathway stimulates osteo-adipogenic progenitor proliferation resulting in increased adipogenesis in fetal rat calvaria cell cultures
Author(s)	Minamizaki, Tomoko; Yoshiko, Yuji; Yoshioka, Hirotaka; Kozai, Katsuyuki; Aubin, Jane E.; Maeda, Norihiko
Citation	Prostaglandins & Other Lipid Mediators , 97 (3-4) : 97 - 102
Issue Date	2012-03
DOI	10.1016/j.prostaglandins.2012.01.001
Self DOI	
URL	https://ir.lib.hiroshima-u.ac.jp/00049713
Right	© 2012. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This is not the published version. Please cite only the published version. この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。
Relation	

The EP4-ERK-dependent pathway stimulates osteo-adipogenic progenitor proliferation resulting in increased adipogenesis in fetal rat calvaria cell cultures

Tomoko Minamizaki¹, Yuji Yoshiko^{1, #}, Hirotaka Yoshioka¹, Katsuyuki Kozai², Jane E. Aubin³, Norihiko Maeda¹

¹Department of Oral Growth and Developmental Biology and ²Department of Pediatric Dentistry, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, 734-8553, Japan

³Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, M5S 1A8, Canada

Corresponding author:

[#]Department of Oral Growth and Developmental Biology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
Tel & fax: Japan 82-257-5621

e-mail: yyuji@hiroshima-u.ac.jp

Key words: selective EP agonists, rat calvaria cells, osteogenesis, adipogenesis, ERK pathway

Total number of figures: 5

Total number of tables: 0

Contract grant sponsor: MESSC; Contract grant number: 13771074 (to YY, Japan).

1. Introduction

Four specific G protein-coupled Prostaglandin E₂ (PGE₂) receptor subtypes (EP1-4) have been identified and are known to be differentially expressed across tissue types [1]. EP1 couples to Ca²⁺-dependent protein kinase C (PKC), and EP2 and EP4 share the adenylate cyclase-cAMP-PKA pathway, whereas EP3 antagonizes the EP2/EP4 pathway. These various PGE₂ signaling pathways bring about a large number of physiological and pathophysiological processes [2]. PGE₂ actions in bone are also complicated, but its anabolic effects in rats are obvious, when PGE₂ is administered systemically or locally to the skeleton [3, 4]. Development of selective agonists for each EP receptor subtype agonists, EP1A-4A) [2, 5] and pharmacological [6, 7] and genetic [8] approaches led us conclude that both EP2 and EP4 play a crucial role in PGE₂-mediated bone formation. mitogen-activated protein kinase (MAPK) pathways are considered to be involved in PGE₂ actions in bone [9, 10]. Previously, we found that, of the three principal MAPK pathways, EP2 and EP4 activate the cAMP-p38 MAPK-c-fos/Runx2 pathways, while EP4 also mediates the ERK pathway, possibly via PKC, and c-Jun N-terminal kinase (JNK) in fetal rat calvaria (RC) cells [11].

PGJ₂ appears to be a natural ligand for peroxisome proliferator-activated receptor γ (PPAR γ) [12], a master transcription factor of adipogenesis [13], and cyclooxygenase (COX)-2 is necessary for PGJ₂ production and/or adipogenesis in adipose tissue [2, 14, 15]. On the other hand, COX-2 in bone is mostly involved in PGE₂ production, which in turn increases bone morphogenetic protein 2-dependent bone formation [16]. Together with the involvement of EP2 and EP4 in osteogenesis, EP4 mediates the inhibitory effect of PGE₂ on adipogenic differentiation of 3T3-L1 cells with a concomitant decrease in

PPAR γ mRNA expression [17]. In aged ovariectomized (OVX) rats, EP4A stimulates bone formation at skeletal sites, while it decreases the number of adipocytes and fatty marrow area [4]. In contrast, when we treated fetal rat calvaria (RC) cells with PGE₂ under osteogenic conditions, we found an increase in adipocyte colonies together with increased bone nodule formation. Osteoblasts and adipocytes share a common mesenchymal progenitor cells, and not only bone marrow stromal cells (a mesenchymal stem cell model) but also RC cells (a committed osteoblast precursor pool) [18], can convert into adipocytes in particular situations, such as ectopic overexpression of PPAR γ [12] and treatment with a synthetic PPAR γ ligand [18, 19]. We thus explored in detail the role(s) of PGE₂ in adipogenesis in RC cell cultures under osteogenic conditions.

2. Materials and methods

2.1. Reagents

Selective EP agonists (EP1A, ONO-DI-004; EP2A, ONO-AEI-259; EP3A, ONO-AE-248; EP4A, ONO-AEI-437; each product was guaranteed with >90% purity) were gifts from Ono Pharmaceutical Co. (Osaka, Japan). PGE₂, MAPK inhibitors (for p38 MAPK, SB203580; for JNK, dicumarol; for ERK, U0126) and all other chemicals, unless otherwise specified, were purchased from Sigma-Aldrich Co (St Louis, MO). These reagents were dissolved in dimethylsulfoxide (DMSO) at a final concentration of < 0.1%.

2.2. Animals

Animal use and procedures were approved by the Committee of Research Facilities

for Laboratory Animal Science, Hiroshima. Rats were euthanized by cervical dislocation under deep anesthesia.

2.3. Cell cultures

RC cells were routinely obtained from fetal rat calvaria (embryonic day 21) as described [20]. Briefly, calvariae were minced and digested with collagenase (type I) for 10, 20, 30, 50 and 70 min at 37 °C. Cells retrieved from the last four of five digestion fractions were separately grown in α MEM containing 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA) and antibiotics. After 24 h, cells were pooled and grown in multi-well plates in the same medium supplemented additionally with 50 μ g/ml of ascorbic acid (osteogenic medium). Cells were treated with or without reagents in regular or serum-deprived conditions (see below), as specified. Medium was changed every 2-3 days, and cultures were maintained at 37 °C in a humidified atmosphere with 5% CO₂.

2.4. 5-bromo-2'-deoxyuridine(BrdU)-labeling index

Cells grown in osteogenic medium for 2 days were adapted to serum-deprived conditions (0.1% FCS) for 24 h and treated with or without EP agonists or PGE₂ for an additional 24 h. BrdU-labeled cells were detected immunohistochemically, as described before [11]. Briefly, cells were labeled with BrdU (10 μ M) for 3 h before culture termination, then fixed with 70% ethanol for 30 min, air dried and permeabilized with 2 M HCl for 5 min. Anti-BrdU monoclonal antibody (1:1,000) and horseradish peroxidase-labeled secondary antibody (1:200, Vector Lab, Burlingame, CA) were used with the avidin-biotin complex (ABC) system (Vector Lab).

2.5. MTT assay

Cells were kept under serum-starved conditions (1% FCS) for 24 h and then treated with or without each EP agonist for 48 h, followed by treatment with MTT (3-[4,5-dimethylthiazoyl-2-yl]-2,5-diphenyltetrazolium bromide) for the last 4 h of cultures [11]. Cells were dried, assessed by microscopic examination, and MTT was quantified colorimetrically.

2.6. RNA extraction and real-time RT-PCR

Total RNA was isolated from cells with TRIzol reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's directions. cDNA was synthesized from ≤ 2 μ g of total RNA using ReverTra Ace (TOYOBO, Osaka, Japan) at 50 °C for 40 min. Primer sets for genes of interest were described elsewhere [11, 21]; ribosomal protein L32 (L32) was used as internal control, 5'-CAT GGC TGC CCT TCG GCC TC-3' and 5'-CAT TCT CTT CGC TGC GTA GCC-3'; PPAR γ 2, 5'-TGA CAG TGA CTT GGC CAT ATT T-3' and 5'-TTG TCT TGG ATG TCC TCG AT-3'; CCAAT/enhancer binding protein (C/EBP) δ , 5'-AGA CTC CGA ACG ACC GAT AC-3' and 5'-GTG CCC AAG AAA CTG TAG CA-3'; c-fos, 5'-AGA ATC CGA AGG GAA AGG AA-3' and 5'-ATG ATG CCG GAA ACA AGA AG-3' [11, 18, 19]. Real-time RT-PCR was carried out by using the Light Cycler system (Light CyclerTM DNA Master SYBR[®] Green I; Roche Diagnostics, Indianapolis, IN), according to the manufacturer's instructions.

2.7. Western blotting

Cells under serum-deprived conditions (0.1% FCS) were treated with or without EP4A for 30 min. Cell lysates were obtained and subjected to Western Blotting, as

described [11]. Briefly, cells were lysed in RIPA buffer containing Phosphatase Inhibitor Cocktail (Nacalai Tesque, Kyoto, Japan) and Complete Protease Inhibitor Cocktail (Roche Diagnostics) and, aliquots of the lysates ($\leq 5 \mu\text{g}$ protein/lane) were subjected to SDS-PAGE (15% gels) and electroblotted onto nitrocellulose membranes (Millipore, Bedford, MA). The membranes were probed with antibody against phosphorylated ERK1/2 (p-ERK) (1:1000; Santa Cruz biotechnology), followed by incubation with HRP-conjugated secondary antibody (1:2000, Santa Cruz Biotechnology). Signals were detected by chemiluminescence (Lumi-Light^{PLUS}, Roche Diagnostics). The membranes were reprobed with antibody against non-phosphorylated ERK (1:1000, Santa Cruz Biotechnology).

2.8. Staining for alkaline phosphatase (ALP)/oil red O

Cells were fixed in neutral buffered formalin for 15 min, washed and incubated with AS MX-phosphate/blue LB in 0.1 M Tris-HCl (pH 8.3) to determine osteoid-like nodules. To confirm adipocyte colonies, cells were treated with freshly prepared oil red O for 30 min [19]. In some cases, cells were double stained with ALP and oil red O.

2.9. Statistical analysis

Data from at least three independent experiments are expressed as the mean \pm SD. Statistical differences were evaluated by one-way factorial analysis of variance (ANOVA) and post hoc Tukey's test. A P value less than 0.05 was considered to indicate a significant difference.

3. Results

3.1. *PGE₂ via EP4 acts on the proliferation of primitive osteoprogenitor cells and a consequent increase in adipocyte colonies*

We initially examined the effect of chronic treatment of EP agonists including PGE₂ on adipocyte colony formation during osteoblastogenesis in the RC cell model (14-15 days). Of these ligands, EP4A increased the number of adipocyte colonies (42.5 ± 9.6 , $P < 0.01$), followed by PGE₂ and EP2A (35.8 ± 8.1 , $P < 0.01$, and 24.0 ± 2.7 , $P < 0.05$, respectively), but not by EP1A and EP3A (10.3 ± 3.3 and 10.0 ± 1.6 , respectively) (Figures 1A, B). In contrast, EP2A was the most effective compound in altering bone nodule formation (not shown), as we described before [11]. To elucidate target cells for PGE₂ in adipogenesis versus osteoblastogenesis, we pulse-treated RC cells with PGE₂ for 2 days during three typical osteogenic development stages (see below) as defined by osteoblast markers [11] and counted adipocyte colonies at day 14 (d14). PGE₂ increased the number of adipocyte colonies, when treated during proliferation stages (d3-5) but not differentiation (d7-9) and maturation (d10-12) stages (Figure 2A). These findings differed from the effective time windows for the osteogenic effect of PGE₂ (see ref. [11]).

To determine how PGE₂ exerts adipogenic effect in RC cells, we compared the effect of PGE₂, EP2A and EP4A on cell proliferation by using the MTT assay. As expected, when cells were treated during proliferation stages, EP4A, followed by PGE₂, but not EP2A increased MTT activity (Figure 2B). The effect of EP4A was obvious in monolayer cells (Figure 2C) during proliferation stages but not in nodule-forming multilayer cells during differentiation stages (not shown). These results were confirmed by quantifying the BrdU labeling index during proliferation stages (Figure 2D). We also monitored the

formation of adipocyte colonies over time. By d9, adipocyte colonies were not detectable with or without PGE₂. By d12, adipocyte colonies were seen in non-treatment groups (1.0 ± 0.8 and 2.8 ± 1.0 , respectively) and PGE₂ enhanced these phenomena (4.8 ± 2.1 , $P < 0.05$, and 18.8 ± 3.0 , $P < 0.01$, respectively) (Figure 2E), in parallel with an increase in the number of bone nodules (see ref. [11]). Taken together, these data indicate that an increase in the number of RC cells during proliferation stages is correlated with an increase in number of adipocyte colonies.

3.2. The ERK pathway is involved in EP4-mediated adipogenesis

We described previously that the MAPK pathways mediate PGE₂-dependent bone nodule formation in RC cells [11]. To determine whether MAPKs are also crucial for PGE₂-dependent adipogenesis, we evaluated the effect of SB203580, an inhibitor of p38-MAPK, U0126, an inhibitor of ERK1/2 or dicumarol, an inhibitor of JNK. We treated cells with or without PGE₂, in combination with or without MAPK inhibitors, throughout the culture period. In contrast to SB203580 and dicumarol that increased adipocyte colony formation with or without PGE₂, U0126 decreased the number of adipocyte colonies only in the presence of PGE₂ (Figure 3A). Likewise, the adipogenic effect of EP4A was eliminated by cotreatment with U0126 (Figure 3B). We then treated cells at d3 with or without EP4A under serum-deprived conditions (0.1% FBS) and found that EP4 increased ERK phosphorylation within 30 min (Figure 3C).

Whether EP4 affects gene expression levels of the transcription factors necessary for adipogenesis, such as PPAR γ 2, C/EBP α and C/EBP δ , is of interest. To address this

question, we pretreated cells at d3 with or without U0126, followed by treatment with or without EP4A for 24 h. Using quantitative real-time RT-PCR, we demonstrated that EP4A increased C/EBP δ but not PPAR γ 2 and CEBP α mRNA expression (Figures 4A-C). U0126 alone did not show any effect on these mRNA levels, while it blocked the increased levels of C/EBP δ mRNA induced by EP4A (Figure 4A-C). We also found that EP4A increased mRNA expression of the protooncogene c-fos [22], consistent with our proliferation data; U0126 again attenuated the EP4A effect (Figure 4D). These results suggest that PGE $_2$ may not be directly involved in adipocyte differentiation. Rather, the prostanoid may increase the proliferation of primitive osteo-adipogenic progenitor cells via the EP4-ERK pathway.

4. Discussion

In addition to our previous report that PGE $_2$ acts on osteoblastogenesis via both EP2 and EP4 in RC cell cultures, we now provide evidence that PGE $_2$ also increases adipogenesis in this model, possibly due to its ability to increase the proliferation of primitive osteo-adipogenic progenitor cells principally via the EP4-dependent ERK pathway.

It is worth noting that these results are different from previous studies on 3T3-L1 preadipocytes [17] and aged OVX rats [23], where the EP4 pathway mediates the

anti-adipogenic effect of PGE₂. The ability or not of PGE₂/EP4A to alter the expression of PPAR γ may underlie this discrepancy. We acknowledge that the large proportion of bone nodules versus adipocyte colonies may lead to a difficulty in our ability to detect a change in PPAR γ mRNA expression. However, PPAR γ is constitutively active in the two previous models [13, 24] but not in RC cells; this transcription factor is relatively highly expressed in RC cells during proliferation stages, but its nuclear translocation is not seen without the presence of its ligand [19]. The molecular mechanism(s) of the EP4-dependent downregulation of PPAR γ has not been elucidated, but our findings suggest that EP4 is not directly involved in PPAR γ transactivation at least in RC cells. Although we have not explored the reason why a small number of adipocyte colonies were seen in RC cell cultures without added PGE₂, it seems likely that PGJ₂, a natural ligand of PPAR γ and/or other unknown factors in FBS are involved.

The difference in downstream signaling between EP2A (linked to ERK) and EP4A (linked to p38 MAPK) appears to account for the difference in the adipogenic potency between EP2 and EP4. The difference in target cells between EP2A and EP4A is also notable; EP2A acts mainly on osteogenic cells during differentiation stages, while EP4A acts on less committed primitive osteo-adipogenic progenitor cells with capacity for both osteoblast and adipocyte differentiation [11, 19]. The narrow window of PGE₂ regulation of adipogenesis in RC cells may be the reason why, of four EPs, EP4 is primarily involved in adipogenesis in RC cells. For example, ERK is turned on during proliferation stages, while it is shut-off resulting in low PPAR γ phosphorylation during more mature stages in 3T3-L1 [25]. Our data on the positive effect of p38 MAPK and JNK inhibitors on adipogenesis also support the unique activity of EP4A in adipogenesis. Thus, EP4A increases p38 MAPK and JNK phosphorylation during differentiation stages [11], which may downregulate C/EBP δ and PPAR γ and/or cAMP-response element-binding protein,

as shown in a variety of embryonic and adult adipocyte cell models [26] and mesenchymal stem cells [27].

Even with the activation of PPAR γ , a reciprocal relationship between osteogenesis and adipogenesis was not seen in RC cells [18, 19]. Amongst transcription factors directly involved in adipogenesis [28], C/EBP δ is expressed not only in early preadipocytes to induce PPAR expression [29], but also in osteoblastic cells to regulate osteocalcin expression [30]. Our finding of the EP4A-dependent upregulation of C/EBP δ during proliferation stages appears reasonable in this context. c-fos, a member of the intermediate early gene family, also known as a protooncogene, plays an important role in cell proliferation [31, 32] including rat preadipocytes [33]. In 3T3-L1 preadipocytes, a hormonal adipogenic stimulus triggers the sequential activation of C/EBP δ , followed by C/EBP α and PPAR α [34, 35]. Together with evidence that C/EBP δ is associated with Runx2, a master transcription factor for osteoblastogenesis [36], these results suggest that PGE $_2$ may activate the EP4-c-fos-dependent pathway which promotes the proliferation of osteo-adipogenic progenitor cells and C/EBP δ mRNA expression, resulting in increased adipocyte colonies without a reciprocal decrease in osteoblastogenesis in RC cells.

As summarized in Figure 5, we characterized PGE $_2$ -dependent adipogenic actions in RC cell cultures. Taken together with our previous observation that both EP2 and EP4 act on osteoblastogenesis principally through the MAPK pathways [11], we conclude that EP4 mediates the proliferation of osteo-adipogenic bipotential progenitor cells via the ERK pathway, resulting in adipocyte colony formation concomitant with a massive

increase in bone nodule formation.

5. Acknowledgements

This work was supported in part by grants from the Ministry of Education, Science, Sports and Culture of Japan (13771074 to YY) and Ono Pharmaceutical Co. (to YY), and the Canadian Institutes of Health Research (CIHR; FRN 83704 to JEA)

Figure Legends

Fig. 1. PGE₂ increases the number of adipocyte colonies in RC cell cultures. Cells in 24-well plates were chronically treated with PGE₂, EP2A or EP4A (100 nM each) for 14 days. (A) Representative macrographs of cultures in the presence or absence of PGE₂. The lower right-hand panel is a higher magnification view of the enclosed area in the upper right-hand panel. ALP/oil red O staining. (B) Effect of PGE₂ and EPAs on the number of adipocyte colonies. **P*<0.05 and ***P*<0.01, compared to control (–).

Fig. 2. PGE₂ and EP4A but not EP2A increase proliferation of primitive osteoprogenitor cells. (A) Effect of PGE₂ on the number of adipocyte colonies in three typical development time windows. Cells in 24-well plates were pulse-treated with or without 100 nM PGE₂ for 48 h as indicated and grown up to d14. (B and C) Effect of PGE₂, EP2A and EP4A on cell proliferation. Cells in 96-well plates were treated with PGE₂, EP2A or EP4A (100 nM each) from d3 for 48 h. 0.5% MTT was added for 4 h before culture termination. Panels in (C) show representative micrographs of MTT staining. (D) Effect of PGE₂, EP2A and EP4A on the number of BrdU-labeled cells. Cells in chamber slides under serum-deprived conditions were treated with PGE₂, EP2A or EP4A (100 nM each) for 24 h from d3 to d5 and treated with BrdU for 4 h before culture termination. BrdU-positive cells were detected immunocytochemically. **P*<0.05 and ***P*<0.01, compared to control (–). (E) Chronological changes in adipocyte colony formation. Cells in 24-well plates were treated with or without 100 nM PGE₂ from d3 to d5, and fixed, and stained with oil red O at the days indicated. N.D., not detected.

Fig. 3. The EP4-ERK pathway is involved in adipogenesis. (A) Effect of SB203580,

dicumarol or U0126 on the PGE₂-dependent adipocyte colony formation. Cells were treated with 100 nM PGE₂ in combination with or without 10 μM MAPK inhibitors throughout the culture period. Adipocyte colonies were counted at d14, as described. (B) U0126 inhibits the effect of pulse-treatment with EP4A on adipocyte colony formation. Cells at d3 in 24-well plates were pretreated with or without 10 μM U0126 for 2 h, followed by treatment with or without 100 nM EP4A for an additional 48 h. Adipocyte colonies were counted at d14, as described. (C) Effect of EP4A on ERK phosphorylation. Cells at d3 in 35 mm dishes were treated with or without EP4A for 30 min, and activation of ERK1/2 was determined by Western blot analysis. Left, representative images. Right, quantitative data. **P*<0.05, ***P*<0.01, compared to control (-). #*P*<0.05, ###*P*<0.01, compared to EP4A alone.

Fig. 4. The EP4A-ERK pathway is involved in C/EBPδ and c-fos mRNA expression. Cells at d3 were handled as shown in Figure 3 (B). Total RNA was isolated, and mRNA expression of PPARγ_□ (A), C/EBPα (B), C/EBPδ (C) and c-fos (D) was quantified by real-time RT-PCR. **P*<0.05 and ***P*<0.01, compared to PGE₂ alone. ###*P*<0.01, compared to EP4A alone.

Fig. 5. A schematic diagram of deduced PGE₂-MAPK-dependent osteo-adipogenesis in RC cell cultures. PGE₂ appears to act on both primitive and more committed osteoprogenitor cells. Taken together with our previous study [11], the EP4-ERK and EP2-p38 MAPK pathways act mostly on the former and the latter, respectively. EP4 mediates the proliferation of primitive osteoprogenitor cells which have the potential to differentiate into both osteocytes and adipocytes. In consequence, EP4 may increase

adipocyte colonies, independent of its massive stimulatory effect on bone nodule formation.

References


1. Breyer MD, Breyer RM: **Prostaglandin E receptors and the kidney**. *Am J Physiol Renal Physiol* 2000, **279**(1):F12-23.
2. Narumiya S, FitzGerald GA: **Genetic and pharmacological analysis of prostanoid receptor function**. *J Clin Invest* 2001, **108**(1):25-30.
3. Weinreb M, Rutledge SJ, Rodan GA: **Systemic administration of an anabolic dose of prostaglandin E₂ induces early-response genes in rat bones**. *Bone* 1997, **20**(4):347-353.
4. Aguirre JI, Leal ME, Rivera MF, Vanegas SM, Jorgensen M, Wronski TJ: **Effects of basic fibroblast growth factor and a prostaglandin E₂ receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats**. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* 2007, **22**(6):877-888.
5. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T: **The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs**. *Endocrinology* 2000, **141**(4):1554-1559.
6. Paralkar VM, Borovecki F, Ke HZ, Cameron KO, Lefker B, Grasser WA, Owen TA, Li M, DaSilva-Jardine P, Zhou M *et al*: **An EP2 receptor-selective prostaglandin E₂ agonist induces bone healing**. *Proc Natl Acad Sci U S A* 2003, **100**(11):6736-6740.
7. Li M, Ke HZ, Qi H, Healy DR, Li Y, Crawford DT, Paralkar VM, Owen TA, Cameron KO, Lefker BA *et al*: **A novel, non-prostanoid EP2 receptor-selective prostaglandin E₂ agonist stimulates local bone formation and enhances fracture healing**. *J Bone Miner Res* 2003, **18**(11):2033-2042.
8. Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, Yamaguchi K, Segi E, Tsuboyama T, Matsushita M *et al*: **Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation**. *Proc Natl Acad Sci U S A* 2002, **99**(7):4580-4585.
9. Ghayor C, Rey A, Caverzasio J: **Prostaglandin-dependent activation of ERK mediates cell proliferation induced by transforming growth factor beta in mouse osteoblastic cells**. *Bone* 2005, **36**(1):93-100.
10. Tokuda H, Kozawa O, Niwa M, Matsuno H, Kato K, Uematsu T: **Mechanism of prostaglandin E₂-stimulated heat shock protein 27 induction in osteoblast-like MC3T3-E1 cells**. *J Endocrinol* 2002, **172**(2):271-281.
11. Minamizaki T, Yoshiko Y, Kozai K, Aubin JE, Maeda N: **EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E₂ on bone formation in rat calvaria cell cultures**. *Bone* 2009, **44**(6):1177-1185.
12. Kim SW, Her SJ, Kim SY, Shin CS: **Ectopic overexpression of adipogenic transcription factors induces transdifferentiation of MC3T3-E1 osteoblasts**. *Biochem Biophys Res Commun* 2005, **327**(3):811-819.
13. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM: **A prostaglandin J₂ metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation**. *Cell* 1995, **83**(5):813-819.
14. Fain JN, Ballou LR, Bahouth SW: **Obesity is induced in mice heterozygous for cyclooxygenase-2**. *Prostaglandins Other Lipid Mediat* 2001, **65**(4):199-209.

15. Ghoshal S, Trivedi DB, Graf GA, Loftin CD: **Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice.** *The Journal of biological chemistry* 2011, **286**(1):889-898.
16. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ: **Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair.** *The Journal of clinical investigation* 2002, **109**(11):1405-1415.
17. Tsuboi H, Sugimoto Y, Kainoh T, Ichikawa A: **Prostanoid EP4 receptor is involved in suppression of 3T3-L1 adipocyte differentiation.** *Biochem Biophys Res Commun* 2004, **322**(3):1066-1072.
18. Hasegawa T, Oizumi K, Yoshiko Y, Tanne K, Maeda N, Aubin JE: **The PPAR γ -selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations.** *BMC Dev Biol* 2008, **8**:71.
19. Yoshiko Y, Oizumi K, Hasegawa T, Minamizaki T, Tanne K, Maeda N, Aubin JE: **A subset of osteoblasts expressing high endogenous levels of PPAR γ switches fate to adipocytes in the rat calvaria cell culture model.** *PLoS One* 2010, **5**(7):e11782.
20. Bellows CG, Sodek J, Yao KL, Aubin JE: **Phenotypic differences in subclones and long-term cultures of clonally derived rat bone cell lines.** *J Cell Biochem* 1986, **31**(2):153-169.
21. Yoshiko Y, Maeda N, Aubin JE: **Stanniocalcin 1 stimulates osteoblast differentiation in rat calvaria cell cultures.** *Endocrinology* 2003, **144**(9):4134-4143.
22. Riabowol KT, Vosatka RJ, Ziff EB, Lamb NJ, Feramisco JR: **Microinjection of fos-specific antibodies blocks DNA synthesis in fibroblast cells.** *Mol Cell Biol* 1988, **8**(4):1670-1676.
23. Aguirre JI, Leal ME, Rivera MF, Vanegas SM, Jorgensen M, Wronski TJ: **Effects of basic fibroblast growth factor and a prostaglandin E₂ receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats.** *J Bone Miner Res* 2007, **22**(6):877-888.
24. Fajas L, Fruchart JC, Auwerx J: **Transcriptional control of adipogenesis.** *Current opinion in cell biology* 1998, **10**(2):165-173.
25. Bost F, Aouadi M, Caron L, Binetruy B: **The role of MAPKs in adipocyte differentiation and obesity.** *Biochimie* 2005, **87**(1):51-56.
26. Aouadi M, Laurent K, Prot M, Le Marchand-Brustel Y, Binetruy B, Bost F: **Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages.** *Diabetes* 2006, **55**(2):281-289.
27. Tominaga S, Yamaguchi T, Takahashi S, Hirose F, Osumi T: **Negative regulation of adipogenesis from human mesenchymal stem cells by Jun N-terminal kinase.** *Biochem Biophys Res Commun* 2005, **326**(2):499-504.
28. Wu Z, Puigserver P, Spiegelman BM: **Transcriptional activation of adipogenesis.** *Current opinion in cell biology* 1999, **11**(6):689-694.
29. Wu Z, Bucher NL, Farmer SR: **Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBP β , C/EBP δ , and glucocorticoids.** *Molecular and cellular biology* 1996, **16**(8):4128-4136.
30. Shin CS, Jeon MJ, Yang JY, Her SJ, Kim D, Kim SW, Kim SY:

- CCAAT/enhancer-binding protein δ activates the Runx2-mediated transcription of mouse osteocalcin II promoter.** *J Mol Endocrinol* 2006, **36**(3):531-546.
31. Ovitt CE, Ruther U: **The proto-oncogene c-fos: structure, expression, and functional aspects.** *Oxf Surv Eukaryot Genes* 1989, **6**:33-51.
32. Angel P, Karin M: **The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.** *Biochim Biophys Acta* 1991, **1072**(2-3):129-157.
33. Machinal-Quelin F, Dieudonne MN, Leneuve MC, Pecquery R, Giudicelli Y: **Preadipogenic effect of leptin on rat preadipocytes in vitro: activation of MAPK and STAT3 signaling pathways.** *Am J Physiol Cell Physiol* 2002, **282**(4):C853-863.
34. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM: **Transcriptional regulation of adipogenesis.** *Genes Dev* 2000, **14**(11):1293-1307.
35. Gregoire FM, Smas CM, Sul HS: **Understanding adipocyte differentiation.** *Physiol Rev* 1998, **78**(3):783-809.
36. Gutierrez S, Javed A, Tennant DK, van Rees M, Montecino M, Stein GS, Stein JL, Lian JB: **CCAAT/enhancer-binding proteins (C/EBP) β and δ activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression.** *The Journal of biological chemistry* 2002, **277**(2):1316-1323.

Figure 1

A



B




Figure 2








Figure 3






Figure 4




Figure 5

